{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-252544","form_type":"8-K","ticker":"MNKD","cik":"0000899460","company_name":"MANNKIND CORP","filed_at":"2026-06-02T12:00:36+00:00","discovered_at":"2026-06-02T12:05:00.257937+00:00","generated_at":"2026-06-02T12:05:11.428887+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FDA approves Afrezza for pediatric diabetes patients ages 6+","bullets":["FDA approved supplemental BLA for Afrezza (insulin human) Inhalation Powder for children and adolescents aged 6 and older with type 1 and type 2 diabetes.","More than 350,000 U.S. children and adolescents live with diabetes; majority have type 1 and require lifelong insulin.","Approval fulfills the last postmarketing requirement from the original June 27, 2014 approval letter.","MannKind expects to expand the patient population for Afrezza beyond adults."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-252544","json":"https://secwatch.observer/filing/0001193125-26-252544.json","markdown":"https://secwatch.observer/filing/0001193125-26-252544.md","text":"https://secwatch.observer/filing/0001193125-26-252544.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899460/000119312526252544/0001193125-26-252544-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899460/000119312526252544/mnkd-20260529.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T12:05:11.428887+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001493152-26-026760","ticker":"CING","company_name":"Cingulate Inc.","filed_at":"2026-06-02T12:10:25+00:00","headline":"Cingulate receives FDA Complete Response Letter for CTx-1301; no safety/efficacy issues, CMC-only","event_type":"regulatory","sec_items":["7.01","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026760","json":"https://secwatch.observer/filing/0001493152-26-026760.json","markdown":"https://secwatch.observer/filing/0001493152-26-026760.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1862150/000149315226026760/0001493152-26-026760-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1862150/000149315226026760/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-252475","ticker":"VERA","company_name":"Vera Therapeutics, Inc.","filed_at":"2026-06-02T11:05:16+00:00","headline":"Vera Therapeutics announces FDA alignment on earlier eGFR analysis for atacicept; results expected Q3 2026","event_type":"regulatory","sec_items":["8.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-252475","json":"https://secwatch.observer/filing/0001193125-26-252475.json","markdown":"https://secwatch.observer/filing/0001193125-26-252475.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831828/000119312526252475/0001193125-26-252475-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831828/000119312526252475/vera-20260602.htm"},"side_by_side_evidence":null},{"accession":"0001108426-26-000030","ticker":"TXNM","company_name":"TXNM ENERGY INC","filed_at":"2026-06-01T21:54:12+00:00","headline":"TXNM subsidiaries: TNMP rate settlement with $20.5M storm rider, PNM resource plan with 1.65 GW renewables","event_type":"regulatory","sec_items":["7.01","8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001108426-26-000030","json":"https://secwatch.observer/filing/0001108426-26-000030.json","markdown":"https://secwatch.observer/filing/0001108426-26-000030.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108426/000110842626000030/0001108426-26-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/22767/000110842626000030/pnm-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-251517","ticker":"LESL","company_name":"Leslie's, Inc.","filed_at":"2026-06-01T20:28:42+00:00","headline":"Leslie's regains Nasdaq compliance for minimum market value of publicly held shares","event_type":"regulatory","sec_items":["8.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251517","json":"https://secwatch.observer/filing/0001193125-26-251517.json","markdown":"https://secwatch.observer/filing/0001193125-26-251517.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821806/000119312526251517/0001193125-26-251517-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821806/000119312526251517/lesl-20260529.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-068659","ticker":"OTLK","company_name":"Outlook Therapeutics, Inc.","filed_at":"2026-06-01T13:15:32+00:00","headline":"Outlook Therapeutics resubmits BLA for ONS-5010 to FDA; Class 1 review, PDUFA in 60 days","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068659","json":"https://secwatch.observer/filing/0001104659-26-068659.json","markdown":"https://secwatch.observer/filing/0001104659-26-068659.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926068659/0001104659-26-068659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926068659/tm2616461d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-068591","ticker":"VYGR","company_name":"Voyager Therapeutics, Inc.","filed_at":"2026-06-01T12:00:26+00:00","headline":"FDA clears IND for VY1706, Voyager's tau-silencing gene therapy for Alzheimer's","event_type":"regulatory","sec_items":["8.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068591","json":"https://secwatch.observer/filing/0001104659-26-068591.json","markdown":"https://secwatch.observer/filing/0001104659-26-068591.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000110465926068591/0001104659-26-068591-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000110465926068591/tm2616041d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001476840-26-000050","ticker":"EXFY","company_name":"Expensify, Inc.","filed_at":"2026-05-29T21:15:09+00:00","headline":"Expensify regains Nasdaq minimum bid price compliance","event_type":"regulatory","sec_items":["8.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001476840-26-000050","json":"https://secwatch.observer/filing/0001476840-26-000050.json","markdown":"https://secwatch.observer/filing/0001476840-26-000050.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1476840/000147684026000050/0001476840-26-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1476840/000147684026000050/exfy-20260528.htm"},"side_by_side_evidence":null},{"accession":"0001178913-26-002988","ticker":"SLXN","company_name":"Silexion Therapeutics Corp","filed_at":"2026-05-29T11:00:25+00:00","headline":"Silexion Therapeutics completes 1-for-10 reverse share split; warrants adjusted","event_type":"regulatory","sec_items":["3.03","5.03","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-002988","json":"https://secwatch.observer/filing/0001178913-26-002988.json","markdown":"https://secwatch.observer/filing/0001178913-26-002988.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002988/0001178913-26-002988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002988/zk2635442.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}